Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors

OBJECTIVE: To determine whether changes in standard and novel risk factors during the ACT NOW trial explained the slower rate of CIMT progression with pioglitazone treatment in persons with prediabetes. METHODS AND RESULTS: CIMT was measured in 382 participants at the beginning and up to three addit...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Saremi, Aramesh, Schwenke, Dawn C., Buchanan, Thomas A., Hodis, Howard N., Mack, Wendy J., Banerji, MaryAnn, Bray, George A., Clement, Stephen C., Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Tripathy, Devjit, DeFronzo, Ralph A., Reaven, Peter D.
Format: Artigo
Język:Inglês
Wydane: 2012
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3908828/
https://ncbi.nlm.nih.gov/pubmed/23175674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.112.300346
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy